Bibliographic Details
| Title: |
QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia. |
| Authors: |
Barreto, Jason N.1 (AUTHOR) Barreto.jason@mayo.edu, Cullen, Michael W.2 (AUTHOR), Mara, Kristin C.3 (AUTHOR), Grove, Meagan E.1 (AUTHOR), Sierzchulski, Amanda G.1 (AUTHOR), Dahl, Nathan J.1 (AUTHOR), Tosh, Pritish K.4 (AUTHOR), Dierkhising, Ross A.3 (AUTHOR), Patnaik, Mrinal M.5 (AUTHOR), Ackerman, Michael J.6,7,8 (AUTHOR) |
| Source: |
Leukemia & Lymphoma. Dec2019, Vol. 60 Issue 14, p3512-3520. 9p. |
| Subject Terms: |
*ACUTE leukemia, *MYELODYSPLASTIC syndromes, *FEBRILE neutropenia, *HEMATOLOGIC malignancies, *PREVENTIVE medicine, *GRASS tetany |
| Abstract: |
Benefits of serial electrocardiographic (ECG) monitoring to detect QT prolongation in patients with hematological malignancies remain unclear. This retrospective, single-center, study evaluated 316 adult acute leukemia and high-risk MDS patients who received 11,775 patient-days of voriconazole prophylaxis during induction chemotherapy. Of these, 37 patients (16.2%) experienced QTc prolongation. Medications associated with QTc prolongation included furosemide, haloperidol, metronidazole, mirtazapine, prochlorperazine, and venlafaxine. Hypokalemia and hypomagnesemia were also significantly associated with QTc prolongation (HR 3.15; p =.003 and HR 6.47, p =.007, respectively). Management modifications due to QTc prolongation included discontinuation of QT prolonging medications (n = 25), more aggressive electrolyte repletion (n = 5), and enhanced ECG monitoring (n = 3). One patient with multiple QT prolonging factors experienced possible Torsades de Pointes. Overall mortality was 15% with no cardiac-related deaths. Serial ECG monitoring during induction chemotherapy can be tailored proportionally to QT-prolonging risk factors. Management should include aggressive electrolyte repletion and avoidance of concurrent QT prolonging medications. [ABSTRACT FROM AUTHOR] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
